RPGR Gene Therapy for Retinitis Pigmentosa
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa.
Mini-Bioreactor for Enhanced Organoid Culture
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a mini-bioreactor designed to enhance organoid culture outcomes.
Detection of Organomercurial Compound Biosynthesis in Microbial Communities
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative detection methods for organomercurial biosynthesis in microbial communities.
Targeted Disruption of Rpe65 Gene for Retinal Disease Research
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies.
Snapwell Shipping Container for Live Cell Cultures
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel shipping container designed to protect live cell cultures during transport.
Innovative Gene Therapy for Retinal Diseases
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases.
Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases.
Immunosuppressive Exosomes for Treating Autoimmune Diseases
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases.
Gene Therapy for Leber Congenital Amaurosis
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV gene therapy for Leber Congenital Amaurosis caused by CEP290 mutations.
Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon-gamma as a therapeutic agent for proliferative eye diseases.